mTOR inhibitors sensitize thyroid cancer cells to cytotoxic effect of vemurafenib

Treatment options for advanced metastatic thyroid cancer patients are limited. Vemurafenib, a BRAFV600E inhibitor, has shown promise in clinical trials although cellular resistance occurs. Combination therapy that includes BRAFV600E inhibition and avoids resistance is a clinical need. We used an in...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Hanly, Elyse K., Bednarczyk, Robert B., Tuli, Neha Y., Moscatello, Augustine L., Halicka, H. Dorota, Li, Jiangwei, Geliebter, Jan, Darzynkiewicz, Zbigniew, Tiwari, Raj K.
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2015
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4741856/
https://ncbi.nlm.nih.gov/pubmed/26284586
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados